NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
71288-0114-50 | 71288-0114 | GEMCITABINE HYDROCHLORIDE | GEMCITABINE | 1.0 g/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov. 1, 2018 | In Use | |
63539-0295-30 | 63539-0295 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 10, 2018 | In Use | |
68382-0997-10 | 68382-0997 | Arsenic trioxide | Arsenic trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov. 14, 2018 | In Use | |
67457-0316-25 | 67457-0316 | decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 10, 2018 | In Use | |
00069-9144-11 | 00069-9144 | Docetaxel | Docetaxel | 200.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | June 23, 2014 | April 30, 2017 | No Longer Used |
00069-9144-22 | 00069-9144 | Docetaxel | Docetaxel | 200.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | June 23, 2014 | Feb. 20, 2015 | No Longer Used |
00409-0369-01 | 00409-0369 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 28, 2017 | March 28, 2017 | No Longer Used |
67457-0531-02 | 67457-0531 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 28, 2018 | In Use | |
67457-0532-08 | 67457-0532 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 28, 2018 | In Use | |
69097-0516-07 | 69097-0516 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan. 18, 2019 | In Use | |
69097-0517-07 | 69097-0517 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan. 18, 2019 | In Use | |
72485-0201-01 | 72485-0201 | azacitidine | AZACITIDINE | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sept. 10, 2018 | In Use | |
69097-0364-36 | 69097-0364 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | March 11, 2019 | In Use | |
71288-0106-10 | 71288-0106 | Bleomycin Sulfate | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Aug. 31, 2018 | In Use | |
71288-0107-20 | 71288-0107 | Bleomycin Sulfate | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Aug. 31, 2018 | In Use | |
69539-0019-60 | 69539-0019 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 2, 2018 | In Use | |
69539-0019-99 | 69539-0019 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 2, 2018 | In Use | |
69539-0020-92 | 69539-0020 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 2, 2018 | In Use | |
69539-0020-99 | 69539-0020 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 2, 2018 | In Use | |
72205-0007-92 | 72205-0007 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 21, 2018 | In Use | |
72485-0204-60 | 72485-0204 | Capecitabine | Capecitabine 150mg | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2019 | In Use | |
72485-0205-12 | 72485-0205 | Capecitabine | Capecitabine 500mg | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2019 | In Use | |
59676-0040-28 | 59676-0040 | Erdafitinib | BALVERSA | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | April 12, 2019 | In Use | |
59676-0040-56 | 59676-0040 | Erdafitinib | BALVERSA | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | April 12, 2019 | In Use | |
59676-0050-28 | 59676-0050 | Erdafitinib | BALVERSA | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | April 12, 2019 | In Use |
Found 10,000 results in 7 milliseconds — Export these results